We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Allergy Therapeutics
On the starting blocks towards key data expected in 2023MaxCyte
Vertex Pharmaceuticals secures exa-cel SPLAvacta
Building Tx and Dx portfolios from proprietary platformsHUTCHMED
FRESCO-2 data support broad uptake in later-line mCRCArecor Therapeutics
Broadening opportunities and preparing for the futureFutura Medical
Interims highlight positive first signs in key marketsArecor Therapeutics
Key clinical diabetes events on track for H222HUTCHMED
Rich and diverse pipeline with multiple waves of growthMaxCyte
Strategic investments to support partners & future growthHUTCHMED
On the right track